Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 14/20 | 0.91 |
| ▸ | ABL1 | P00519 | 13/20 | 0.91 |
| ▸ | BCR | P11274 | 9/20 | 0.91 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.91 |
| ▸ | PRKCA | P17252 | 3/20 | 0.91 |
| ▸ | EGFR | P00533 | 2/20 | 0.91 |
| ▸ | KIT | P10721 | 5/20 | 0.78 |
| ▸ | JAK3 | P52333 | 1/20 | 0.74 |
| ▸ | BTK | Q06187 | 1/20 | 0.74 |
| ▸ | ITK | Q08881 | 1/20 | 0.74 |
| ▸ | SRC | P12931 | 1/20 | 0.74 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.74 |
| ▸ | KDR | P35968 | 1/20 | 0.73 |
| ▸ | ABL2 | P42684 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29498750 | 0.95 | PDGFRA (1.00) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL9782 | 0.95 | PDGFRA (1.00) | PDGFRAABL1BCRPDGFRBPRKCA | |
| Methane SCHEMBL5972158 | 0.94 | PDGFRA (0.98) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL13492338 | 0.92 | PDGFRA (0.83) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL9820 | 0.92 | PDGFRA (1.00) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL12034590 | 0.92 | PDGFRA (0.77) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL3230669 | 0.92 | PDGFRA (0.81) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL3055349 | 0.91 | PDGFRA (0.89) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL13498211 | 0.91 | PDGFRA (0.88) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL4801110 | 0.91 | ABL1 (0.84) | PDGFRAABL1BCRPDGFRBPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1721609-A2 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC Biotech AG (DE) | 2006-11-15 | — | — | EP | claimed |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2006-09-28 | — | — | US | claimed |
| EP-1395261-B1 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | GPC BIOTECH AG (DE) | 2006-06-28 | — | — | EP | claimed |
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2003-09-18 | — | — | US | claimed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20150309021-A1 | Advanced Drug Development and Manufacturing | LOS ALAMOS NATIONAL SECURITY, LLC | 2015-10-29 | — | — | US | disclosed |
| EP-2511844-B1 | X-ray microscope | XRPRO SCIENCES INC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| US-20080187575-A1 | Pyrimidine Derivatives | VICHEM CHEMIE KFT (HU) | 2008-08-07 | — | — | US | disclosed |
| EP-1786781-A2 | PYRIMIDINE DERIVATIVES | GPC Biotech AG (DE) | 2007-05-23 | — | — | EP | disclosed |
| EP-1721609-A2 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC Biotech AG (DE) | 2006-11-15 | — | — | EP | disclosed |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2006-09-28 | — | — | US | disclosed |
| EP-1395261-B1 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | GPC BIOTECH AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2006021458-A2 | PYRIMIDINE DERIVATIVES | GPC BIOTECH AG (DE) | 2006-03-02 | — | — | WO | disclosed |
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | PRNP, PPM1D, PPM1F | PDGFRA 2586/4885ABL1 901/4885BCR 1338/4885 |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | PRNP, PPM1D, PPM1F | PDGFRA 2913/4885ABL1 904/4885BCR 1230/4885 |
| US-20080187575-A1 | Pyrimidine Derivatives | TYMP, TDP1, PNP | PDGFRA 373/4885ABL1 2843/4885BCR 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.